Pelthos Therapeutics Inc.
PTHS
About: Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
Employees: 11
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.75% less ownership
Funds ownership: 0.98% [Q1] → 0.23% (-0.75%) [Q2]
44% less funds holding
Funds holding: 9 [Q1] → 5 (-4) [Q2]
78% less capital invested
Capital invested by funds: $846K [Q1] → $187K (-$659K) [Q2]
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Oppenheimer
Jeff Jones
|
$50
|
Outperform
Initiated
|
2 Sep 2025 |
Financial journalist opinion
